Slide 1: Managing Director's Report 12 Months to 31 July 2017
For personal use only Managing Director’s Report 12 Months to 31 July 2017 20 September 2017
Slide 2: Vision and Mission Statement
Vision and Mission Statement For personal use only Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to the adults, infants, children and medical food markets. 1
Slide 3: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total Revenue New products released to $47.9m up 12% develop additional market segments in Sports driven by improved Nutrition demand; highest ever recorded revenue Inventory at $18.8m Net Profit $3.6m up up 33% on prior year to meet increas
Slide 4: Full Year 2017 Results
For personal use only Full Year 2017 Results AUD million 4E Reported 4E Reported 11.5% year on year revenue 31 Jul 2017 31 Jul 2016 growth Revenue $47.9 $42.9 Increased sales across all EBITDA $6.1 $3.3 markets EBIT $5.5 $2.8 EBIT $5.5m (PY $2.8m) NPBT $5.0 $3.1 NPBT of $5.0m includes Tax ($
Slide 5: Balance Sheet July 2017
Balance Sheet 31 July 2017 For personal use only AUD million Reported Reported Movement 31 July 2017 31 July 2016 Cash balance strong $5.9m Cash $5.9 $8.2 2.3 Trade $12.1 $10.9 1.2 Trade receivables Receivables reflect the Inventories $18.8 $13.6 5.2 increased sales activity Total Current
Slide 6: Sales by Geography & Product
For personal use only Sales by Geography & Product Sales across all regions Encapsulated Tuna oil have grown during 2017 leads sales revenue with encapsulated Algal oils and European and American other oils represented in markets provide new other products opportunities FY 2017 Geographic FY 2
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Infant Market formula Development customers Product Development 6
Slide 8: Growth Platform: Infant formula provides further growth
For personal use only Growth Platform Market Infant formula Development customer s Infant formula provides further growth Product Development The Chinese regulators changed rulings during 2017. Initially they proposed banning ‘grey imports’ (called CBEC) closing the channel to market for many infa
Slide 9: Products for new segments
Market Infant formula Development customers For personal use only Growth Platform Product Development Products for new segments Clover’s Hypoallergenic DHA product is now being purchased and used in infant formula applications A new highly concentrated DHA product which delivers 60% oil in a pow
Slide 10: New markets development
For personal use only Growth Platform Market Development Infant formula customers New markets development Product Development Clover has aligned with distributors across the USA, Europe & Asia, providing market access and the capability to service new customer opportunities To generate a presenc
Slide 11: FY2018 Outlook & Priorities
For personal use only FY2018 Outlook & Priorities Further market development through a specialised distribution network Product development enhancing our capability to fortify foods, drinks and other products with Omega 3 Growth into new markets of India and the Middle East Research & Develo
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s